When taking both LAG-3 and PD-L1 expression into account, patients whose tumor cells are PD-L1− and LAG-3− TILs have longer RFS than patients who are PD-L1+ or LAG-3+ or both positive [203]. This evidence concerns the gene CD274 and neoplasm.